Angiotensin II: A vasoactive hormone with ever-increasing biological roles

Circulation Research

Volumn 92, Issue 1, 2003, Pages 9-11

  Taubman, Mark B ^a  

^a NONE

Author keywords

Angiotensin II; Arterial injury; Gene array; Smooth muscle cells

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LACTATE DEHYDROGENASE; OSTEOPONTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN LYSINE 6 OXIDASE; THROMBOSPONDIN; VASOACTIVE AGENT;

BLOOD VESSEL REACTIVITY; CALCIUM MOBILIZATION; CARDIOVASCULAR RESPONSE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DNA HYBRIDIZATION; DNA MICROARRAY; EDITORIAL; GENE EXPRESSION REGULATION; HEART FAILURE; HEART VENTRICLE REMODELING; HORMONE DETERMINATION; HUMAN; HYPERTENSION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; TECHNOLOGY; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HORMONES; HUMANS; MUSCLE, SMOOTH, VASCULAR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOME; RATS; REPRODUCIBILITY OF RESULTS;

EID: 0037428057     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000052920.70316.AE     Document Type: Editorial

References (23)

1. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension. 2001;38:1382-1387.
2. Geisterfer AA. Peach M J, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988;62:749-756.
3. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension. 1989;13:305-314.
4. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 1991;351:233-236.
5. Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, Matsuda Y, Inagami T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature. 1991;351:230-233.
6. Berk BC,. Corson MA. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res. 1997;80:607-616.
7. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension. 1997;29:366-373.
8. Chamley-Campbell JH, Campbell GR, Ross R. Phenotype -dependent response of cultured aortic smooth muscle to serum mitogens. J Cell Biol. 1981;89:379-383.
9. Naftilan AJ. The role of angiotensin II in vascular smooth muscle cell growth. J Cardiovasc Pharmacol. 1992;20(suppl 1):S37-S40.
10. Brown NJ, Vaughan DE, Prothrombotic effects of angiotensin. Adv Intern Med. 2000;45:419-429.
11. Phillips MI, Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs. 2002;3:569-577.
12. Green RS, Lieb ME, Weintraub AS, Gacheru SN, Rosenfield CL, Shah S, Kagan HM, Taubman MB. Identification of lysyl oxidase and other platelet-derived growth factor-inducible genes in vascular smooth muscle cells by differential screening. Lab Invest. 1995;73:476-482.
13. Giachelli C. Bae N, Lombardi D, Majesky M, Schwartz S. Molecular cloning and characterization of 2B7. a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biochem Biophys Res Commun 1991;177:867-873.
14. Campos AH, Zhao Y, Pollman MJ, Gibbons GH. DNA microarray profiling to identify angiotensin-responsive genes in vascular smooth muscle cells: potential mediators of vascular disease. Circ Res. 2003;92:111-118.
15. Clowes AW, Clowes MM, Fingerle J, Reidy MA. Regulation of smooth muscle cell growth in injured artery. J Cardiovasc Pharmacol. 1989;14:S12-S15.
16. Schwartz SM, Liaw L. Growth control and morphogenesis in the development and pathology of arteries. J Cardiovasc Pharmacol. 1993;21:S31-S49.
17. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995:57:791-804.
18. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation. 1992;86(suppl III):III-43-III-46.
19. Prescott MF, Webb RL, Reidy MA. Angiotensin-converting enzyme inhibitor versus angiotensin II, ATI receptor antagonist: effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol. 1991;139:1291-1296.
20. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993;92:1686-1696.
21. Hasenstab D, Forough R, Clowes AW. Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats. Circ Res. 1997;80:490-496.
22. Wang H, Moore S, Alavi MZ. Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in rabbit aortic neointima after selective de-endothelialization. Atherosclerosis. 1996;126:95-104.
23. Patton WF, Erdjument-Bromage H, Marks AR, Tempst P, Taubman MB. Components of the protein synthesis and folding machinery are induced in vascular smooth muscle cells by hypertrophic and hyperplastic agents: identification by comparative protein phenotyping and microsequencing. J Biol Chem. 1995;270:21404-21410.